Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/20/2025 | $45.00 | Outperform | Noble Capital Markets |
| 9/1/2021 | $78.00 | Buy | HC Wainwright & Co. |
STAFFORD, Texas, June 01, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an immunotherapy to prevent breast cancer recurrences, today presents the published abstract and poster from the ASCO Annual Meeting 2026. The abstract is shown below and the poster being presented today can be seen and downloaded at the bottom of the Phase III clinical trial tab on the Company's website here. This is the second abstract and poster presented jointly with the Steering Committee of FLAMINGO-01 with statistically signi
STAFFORD, Texas, June 01, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an immunotherapy to prevent breast cancer recurrences, today provided an update on its Form 10-K filing for the fiscal year ending December 31, 2025. The Form 10-K for the fiscal year ending December 31, 2025, continues to be audited by our new auditor and we believe it is in the final approval steps. The Form 10-K also includes the 2024 audit that was previously audited by the prior auditor. As previously indicated, the accounts pay
STAFFORD, Texas, May 22, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) ("Greenwich" or the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced that on May 20, 2026, the Company received notification from the Listing Qualifications Department of The Nasdaq Stock Market LLC notifying the Company that, because it has not yet filed its Quarterly Report on Form 10-Q for the three months ended March 31, 2026, the Company is not currently in compliance with Nasdaq Listing Rule 5250(c)(1), which req
4 - Greenwich LifeSciences, Inc. (0001799788) (Issuer)
4 - Greenwich LifeSciences, Inc. (0001799788) (Issuer)
4 - Greenwich LifeSciences, Inc. (0001799788) (Issuer)
10-K - Greenwich LifeSciences, Inc. (0001799788) (Filer)
NT 10-K - Greenwich LifeSciences, Inc. (0001799788) (Filer)
8-K - Greenwich LifeSciences, Inc. (0001799788) (Filer)
4 - Greenwich LifeSciences, Inc. (0001799788) (Issuer)
4 - Greenwich LifeSciences, Inc. (0001799788) (Issuer)
4 - Greenwich LifeSciences, Inc. (0001799788) (Issuer)
Noble Capital Markets initiated coverage of Greenwich LifeSciences with a rating of Outperform and set a new price target of $45.00
HC Wainwright & Co. initiated coverage of Greenwich LifeSciences with a rating of Buy and set a new price target of $78.00
Aegis Capital initiated coverage of Greenwich LifeSciences with a rating of Buy and set a new price target of $75.00
SC 13G - Greenwich LifeSciences, Inc. (0001799788) (Subject)